MARIPOSA
from OncoPharm Hosted by John Bossaer
The MARIPOSA study suggests there may be a new preferred first line regimen (amivantamab + lazertinib) for metastatic EGFR-mutated NSCLC, as this regimen improved PFS compared to osimertinib.
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of OncoPharm?
This episode is 10 minutes long.
When was this OncoPharm episode published?
This episode was published on June 27, 2024.
Can I download this OncoPharm episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.